

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **BBI LIFE SCIENCES CORPORATION**

### **BBI 生命科學有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code:1035)**

## **PROFIT ALERT**

This announcement is made by BBI Life Sciences Corporation (the “**Company**”) together with its subsidiaries (collectively referred to as the “**Group**”) pursuant to Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

With the principal operations of the Group achieving stable development and increase in the revenue of the Group, the board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company and potential investors that, based on the preliminary review of the Group’s unaudited consolidated management accounts for the year ended 31 December 2014 (the “**Year**”), the Company expects that, without taking into account the non-recurring gain and expense for the Year comprising of (i) the recognition of listing expense of approximately RMB22.5 million; (ii) expense of share-based payment of approximately RMB13.5 million; and (iii) gain on disposal of a 31.0% equity interest in 上海普欣生物技術有限公司 (Shanghai PrimeGene Bio-Tech Co., Ltd.\*) of approximately RMB26.4 million to a third-party company in April 2014, the amount of the net profit of the Group for the Year may increase by approximately 8-12% as compared to that for the corresponding period in 2013, while the amount of the net profit of the Group after taking into account the above non-recurring gain and expense may decrease by approximately 12-16% as compared to that for the corresponding period in 2013.

The Company is still in the process of finalising the annual results of the Group for the Year. The annual results announcement of the Company for the Year is expected to be published by the end of March 2015. The information contained in this announcement is only a preliminary assessment made by the management of the Company based on the unaudited consolidated management accounts of the Group for the Year, which have not been reviewed by the Company’s Audit Committee.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board of  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
Chairman

Hong Kong, 30 January 2015

*As at the date of this announcement, the executive directors of the Company are Mr. WANG Qisong, Ms. WANG Luoja, and Ms. WANG Jin; the non-executive director of the Company is Mr. HU Xubo; and the independent non-executive directors of the Company are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung, and Mr. LIU Jianjun.*